Literature DB >> 2861523

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

J D Baumgartner, M P Glauser, J A McCutchan, E J Ziegler, G van Melle, M R Klauber, M Vogt, E Muehlen, R Luethy, R Chiolero.   

Abstract

The prophylactic effect of antibody to endotoxin core glycolipid was studied in surgical patients at high risk of gram-negative infection. At randomisation (on admission to intensive care unit), every 5 days thereafter, and at onset of septic shock, patients received plasma taken from donors before (control) or after immunisation with Escherichia coli J5, a mutant with only core determinants in its endotoxin. Gram-negative shock occurred in 15 of 136 controls and 6 of 126 J5 antibody recipients and related deaths in 9 of 136 and 2 of 126, respectively. J5 antibody was most effective in abdominal surgery patients, in whom shock occurred in 13 of 83 controls and 2 of 71 antibody recipients. Although antibody prophylaxis did not lower the infection rate, it prevented the serious consequences of gram-negative infections and thus improved the overall prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861523     DOI: 10.1016/s0140-6736(85)90176-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 3.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 4.  Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.

Authors:  J D Baumgartner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

Review 5.  The adult respiratory distress syndrome. New insights into diagnosis, pathophysiology, and treatment.

Authors:  M A Matthay
Journal:  West J Med       Date:  1989-02

6.  Monoclonal antibodies in sepsis and septic shock.

Authors:  C J Hinds
Journal:  BMJ       Date:  1992-01-18

Review 7.  Immunological perspectives in prevention and treatment of nosocomial pneumonia.

Authors:  J E Pennington
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 8.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 9.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

10.  Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X.

Authors:  R L Danner; K A Joiner; J E Parrillo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.